Home » Topics » Regulatory » EMA

EMA
RSS

MabThera approved in E.U. as maintenance treatment of follicular lymphoma

Nov. 4, 2010

Genta receives EMA advice for phase III tesetaxel trial in gastric cancer

Nov. 3, 2010

E.U. grants authorization for Ruconest in hereditary angioedema

Oct. 29, 2010

EMA recommends changes in prescribing information for Invirase

Oct. 26, 2010

CHMP recommends new indication for Bristol-Myers Squibb's Sprycel

Oct. 26, 2010

CHMP recommends variation of marketing authorization for Pfizer's Sutent

Oct. 26, 2010

CHMP recommends marketing authorization for MedImmune's FluEnz vaccine

Oct. 26, 2010

CHMP issues positive opinion on ranibizumab for DME-related vision impairment

Oct. 25, 2010

EMA initiates review of Orion's centralized MAA for dexmedetomidine

Oct. 22, 2010

EC grants orphan drug status for nafamostat mesilate in cystic fibrosis

Oct. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...